Browsing byAuthorEnners, S
Showing results 1 to 6 of 6
Issue Date | Title | Author(s) |
2021-10 | Impact of angiotensin receptor blocker product recalls on antihypertensive prescribing in Germany. | Rudolph, UM; Enners, S; Kieble, M; Mahfoud, F; Böhm, M; Laufs, U; Schulz, M |
2020-10-21 | Learnings from Regional Market Dynamics of Originator and Biosimilar Infliximab and Etanercept in Germany. | Moorkens, E; Barcina Lacosta, T; Vulto, AG; Schulz, M; Gradl, G; Enners, S; Selke, G; Huys, I; Simoens, S |
2021-07-08 | Quality Appraisal of Ambulatory Oral Cephalosporin and Fluoroquinolone Use in the 16 German Federal States from 2014-2019. | Gradl, G; Werning, J; Enners, S; Kieble, M; Schulz, M |
2022 | Trends in Ezetimibe Prescriptions as Monotherapy or Fixed-Dose Combination in Germany 2012-2021. | Katzmann, JL; Kieble, M; Enners, S; Böhm, M; Mahfoud, F; Laufs, U; Schulz, M |
2022-02-27 | Use of fixed-dose combination antihypertensives in Germany between 2016 and 2020: an example of guideline inertia. | Mahfoud, F; Kieble, M; Enners, S; Kintscher, U; Laufs, U; Böhm, M; Schulz, M |
2021-11 | Utilization of drugs with reports on potential efficacy or harm on COVID-19 before, during, and after the first pandemic wave. | Enners, S; Gradl, G; Kieble, M; Böhm, M; Laufs, U; Schulz, M |